• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a cosmetic composition comprising Ouessant black bee royal jelly in a cosmetically acceptable medium, and its use for the regeneration and / or healing of the skin.
    公开号:FR3061017A1
    申请号:FR1663154
    申请日:2016-12-22
    公开日:2018-06-29
    发明作者:Robin Kurfurst；Lauren Sobilo；Milene Juan；Emmanuelle Leblanc；Olivier JEANNETON；Jean-Christophe Archambault
    申请人:LVMH Recherche GIE；
    IPC主号:
    专利说明:

    Holder (s):
    L V M H RESEARCH.
    O Extension request (s):
    (® Agent (s): REGIMBEAU.
    ® COSMETIC COMPOSITION COMPRISING ROYAL JELLY OF OUESSANT'S BLACK BEE.
    @) The present invention relates to a cosmetic composition comprising royal jelly of black bees of Ouessant in a cosmetically acceptable medium, and its use for the regeneration and / or healing of the skin.
    FR 3,061,017 - A1
    The subject of the present invention is a cosmetic composition promoting the regeneration and / or healing of the skin comprising royal jelly of Ouessant's black bee (Apis mellifera mellifera) in a cosmetically acceptable medium.
    Scarring and tissue regeneration are complex and interrelated processes, involving many cell types, involving multiple regulatory systems, complex cell communication and the secretion of a large number of transcription factors (Martin, 1997) .
    TGF-beta (TGF-β) is the main trigger and regulator of the three main stages of the healing process: inflammation, cell proliferation and tissue remodeling. By its spectrum of activity and its actions upstream of this process, the TGF-β pathway is the biological pathway which makes it possible to accelerate or on the contrary slow down the healing mechanisms.
    TGF-β acts by binding to its cellular receptors forming a type I (TBR-I) and type II (TBR-II) receptor complex and via activation of the smad pathway, thus leads to regulation positive of a set of genes. These genes regulated by TGF-Β are involved in the synthesis of proteins of the extracellular matrix, proliferation and cell motility, the negative regulation of the expression of proteolytic enzymes or the proliferation of dermal fibroblasts.
    The TGF-Β pathway is altered by intrinsic aging and photoaging, thus leading to skin thinning and delayed healing such as those observed for example in the elderly. Another characteristic of aged skin is the reduction in the synthesis of collagen which leads to thinning of the skin and increased fragility. However, a biological action which aims to increase the production or the concentration of TGF-B to reduce the effects of aging would be ineffective since it is an alteration of the TGF-récepteurs receptors which is the cause of the loss of activity of TGF. -Β at the cellular and tissue level.
    Furthermore, TIEG-1 (TGF beta early inducible gene 1) has been identified downstream from the TGF-β pathway, as a key factor in bone regeneration (Subramaniam Ai. Et al. Mol. Cell. Biol., 2005 , 1191-1199), wound healing (Taguchi M. et al., J. Musculoskelet. Res., 2008, 11, 63-69) but also the molecular organization of collagen fibers and the composition of the matrix collagenic (Gumez L. et al., J. Appl. Physiol., 2010, 108, 1706-1710).
    Recent studies reported by Subramaniam M. et al. (Biofactors, 2010, 36, 8-18) have demonstrated the involvement of the gene coding for TIEG-1 in bone regeneration. Indeed, its expression is an element of the primary response of osteoblasts (cells synthesizing the non-mineral part of bones) to TGF-B.
    The identification of the TIEG-1 protein, downstream of the TGF-6 pathway, therefore represents a molecular target of interest for activating the TGF-6 signaling pathway, in particular when the TGF-6 receptors are altered. .
    In this context, the inventors have shown, surprisingly, that the expression of the TIEG-1 gene could be specifically increased under the effect of a new composition comprising royal jelly of Ouessant's black bee (Apis mellifera mellifera ). The inventors have also demonstrated that this composition can improve the regeneration of the skin which is altered by the intrinsic or extrinsic processes of aging or following an attack, for example a physical attack. We will speak in this last case of scarring.
    In particular, the inventors have demonstrated that royal jelly of black bees from Ouessant makes it possible to stimulate the expression of TIEG-1, and in particular within a scar zone compared to a non-scar zone.
    The Ushant black bee is a pure breed of a local ecotype of the Western European Black Bee (Apis mellifera mellifera). The geographic location of Ouessant Island, located more than 20 km from the coast of Finistère, constitutes an insurmountable barrier which has made it possible to protect the Ouessant black bee from any hybridization with other bee species. In addition, the Ouessant Island is an ecosystem that has been protected at all times and this guarantees bees a healthy and diverse environment which gives bees and their products unique characteristics.
    The present invention therefore relates to a cosmetic composition comprising royal jelly of Ouessant's black bee in a cosmetically acceptable medium.
    By “cosmetically acceptable” is meant that the composition is suitable for topical use, in contact with mammalian skin and more particularly human skin.
    Royal jelly is a natural product from beekeeping, which comes in the form of a paste. Unlike “classic” royal jelly, which does not come from Ouessant black bee (Apis mellifera mellifera), Ouessant black bee royal jelly has the advantage of stimulating the expression of TIEG-1, especially in the scar area, in an in vitro healing model by uprooting the cell carpet and recolonization.
    According to a preferred embodiment, the cosmetic composition according to the invention comprises royal jelly of black bees from Ouessant at a concentration of between 0.001% and 1%, preferably between 0.005% and 0.5% and more preferably still between 0.05% and 0.2% by weight of the total composition.
    According to another object of the present invention, the cosmetic composition according to the invention is more particularly intended for the regeneration and / or healing of the skin.
    The composition of the invention is in particular intended for skin exhibiting signs of chronological aging or photoaging.
    In fact, intrinsic or extrinsic aging of the skin causes a slowing down of cell renewal and a degradation of the extracellular matrix to a greater extent than its neosynthesis, which indicates a loss of cutaneous homeostasis. This results in particular in thinning of the skin, sagging of the skin, as well as the appearance of fine lines and wrinkles.
    According to a preferred embodiment, the composition of the invention is intended for topical application.
    The cosmetic composition according to the invention comprises, in addition to Ouessant black bee royal jelly, one or more cosmetic excipients acceptable from those known to those skilled in the art with a view to obtaining a composition for topical application in the form milk, cream, ointment, water-in-oil emulsion, or oil in water, balm, gel, lotion, serum, spray, preferably cream or serum.
    Depending on the nature of the composition, one or more cosmetically acceptable excipients will be selected from polymers, surfactants, rheology agents, perfumes, electrolytes, pH adjusters, antioxidants, preservatives, dyes. , nacres, pigments and their mixtures.
    In a particular embodiment, the cosmetic composition according to the present invention can also comprise at least one cosmetically active agent well known to those skilled in the art chosen from agents for delaying or slowing the appearance of signs of intrinsic skin aging or extrinsic; agents having depigmenting or lightening activity on the skin; agents having slimming activity; agents with hydrating activity; agents having a calming, soothing or relaxing activity; agents stimulating the microcirculation of the skin to improve the radiance of the complexion, in particular of the face; agents having a seboregulatory activity for the care of oily skin; agents for cleaning or purifying the skin; agents having anti-radical activity.
    The cosmetic composition of the invention can thus comprise one or more other substances which can advantageously be chosen from:
    - molecules promoting cell renewal such as retinol and / or its esters; alpha or beta hydroxy acids such as fruit acids, in particular malic acid, glycolic acid or citric acid, salicylic acid or its esters, gentisic acid or its esters, in particular gentisate of tocopherol;
    - molecules or extracts stimulating the firmness of the skin such as peptides that stimulate collagen synthesis, in particular collagen type I, II, IV or VII, an extract of Centella asiatica, madecassic acid, acid Asian, madecassoside, an oat extract, an extract of Berthollétia exscelsa, a protein hydrolyzate or soy peptides, an extract of Potentilla erecta, an extract of Siegesbeckia orientalis, ginsenosides or notoginsenosides, an extract of bark of 'albizia julibrissin, a rosemary leaf extract rich in ursolic acid,
    - molecules or extracts promoting the synthesis of hyaluronic acid or glycosaminoglycans at the epidermal and dermal level, such as an extract Essence vitale from Mamaku, an extract from the leaves of Cyathea medullaris, an extract from Eriobotrya japonica or small fragments of 'low molecular weight hyaluronic acid or even an extract of Adenum obesum;
    - molecules or extracts regulating the differentiation of the epidermis such as ecdysterone, turkesterone, calcium derivatives, vitamin D precursors;
    - adenosine, carnitine or its derivatives in particular acetylcarnitine, cosmetically acceptable ester retinol, in particular propionate or a retinol palmitate;
    - metalloproteinase inhibitors (MMP), in particular inhibitors of MMP 1, 2, 9 such as an extract of Ruscus asculeatus, soy peptides or plant extracts of flavonoids in containers;
    - elastase inhibitors such as plant extracts of Aspergillus fumigatus, Momordica charantia, Cucurbita maxima;
    - a peptide analogous to elastin, advantageously esterified, such as that formed by the palmitoyl-Val-Gly-Val-Ala-Pro-Gly sequence marketed under the trade name BIOPEPTIDE EL by the company SEDERMA;
    - substances capable of stimulating the synthesis of dermatopontin, such as an amber extract;
    - molecules or extracts of astringent plants tightening pores such as an extract of witch hazel; zinc gluconate
    - filters protecting against UVA and UVB radiation, such as benzophenone 4-butyl methoxydibenzoylmethane, ethylhexyl methoxycinnamate, octocrylene, ethylhexyl salicylate, sulfonic acid phenylbenzymidazole, homosalate, alone or in combination with oxides titanium;
    - plant molecules or extracts acting on pigmentation such as kojic acid, extracts of licorice or mulberry root, arbutin, calcium pantothenosulfonate, boldine, diacetylboldine, vitamin C, or one of its derivatives, such as glycosides, extracts of lily in particular of bulb.
    - anti-free radical or anti-inflammatory molecules or extracts such as an extract of Artemisia capillaris, an extract of Sanguisorba officinalis, resveratrol and its derivatives, cucurma, cucurmine or tetrahydrocucurmine, polyphenols extracted from grape seeds, vitamin E and its derivatives, in particular its phosphate derivatives, ergothionein or its derivatives, idebenone,;
    an orchid extract such as an orchid belonging to the genus Brassocattleya, for example an extract of the orchid Brassocattleya marcella, or to the genus Vanda, for example an extract of an orchid from Vanda coerulea, Vanda teres or even Vanda denisoniana ;
    - hydrating agents such as glycerol, trimethyl glycine or natural polyols, natural or synthetic ceramides, spring or mineral waters.
    Advantageously, the composition according to the invention may also comprise a honey or a honey extract. The honey is preferably a unifloral or polyfloral honey.
    Preferably, the honey used in the composition according to the invention can be clover honey (Trifolium repens), Ouessant honey, spurge honey (Euphorbia echinus) or Corsican honey
    In any form whatsoever, the cosmetic composition of the invention is applied to a part of the skin of the body, in particular the face, the neck, the décolleté and / or the hands.
    According to another aspect, the present invention relates to a cosmetic treatment method for stimulating the regeneration of the skin and / or skin scarring, characterized in that a sufficient amount of a cosmetic composition comprising jelly is applied to the skin royal black bee from Ouessant, as a cosmetically active agent.
    The figures and examples below are given by way of illustration and are not limiting.
    FIGURES
    Figure 1: Protein expression of TIEG-1 in an in vitro healing model in FHN.
    A. Diagram of areas of interest where an immunofluorescent signal is quantified in a healing model. Zone A: far from the injured zone; zone B: mixed zone comprising the zone bordering the wound and a control zone on the cell mat; zone C: zone of wound corresponding to the zone scraped by a point of cone; B. Monitoring of the protein expression of TIEG-1 in fibroblasts 48 hours after injury.
    Figure 2: Effect of Ouessant's black bee royal jelly on the protein level of TIEG1 in cultured NHFs in injured (or scar) and non-injured areas.
    Figure 3: Effect of Ouessant black bee royal jelly and black striped yellow bee royal jelly (Buckfast bee) on the synthesis of Collagen type V in cultured NHFs.
    Figure 4: Effect of Ouessant black bee royal jelly and black striped yellow bee royal jelly (Buckfast bee) on elastin synthesis in cultured NHFs.
    EXAMPLES
    Example 1: Expression of TIEG-1 in an in vitro healing model.
    It is possible to obtain, by cell culture, a surface uniformly covered with cells. This carpet can be injured by making a tear by using the tip of a cone which will scrape the cellular carpet.
    On this model, there are 3 different zones: the wound zone corresponding to the zone scraped by the tip of the cone (zone C), a mixed zone, i.e. the zone comprising the zone bordering on the wound (zone B) and a control zone on the cell mat, distant from the injured zone (Zone A) (Figure 1, A). The expression of TIEG-1 was revealed by immunostaining and quantified by image analysis in the fibroblasts present in these three areas when the healing process is initiated.
    This study demonstrates that TIEG-1 is significantly overexpressed in injury zone C by 47% compared to mixed zone B and 53% compared to control zone A (Figure 1, B).
    This indicates that TIEG-1 is a major player in the mechanism of cellular mobility, notably fibroblastic, a major mechanism in the healing process.
    Example 2 Effect of Ouessant's Black Bee Royal Jelly on the Protein Expression of TIEG 1 in Normal Human Fibroblasts (FHN) in Culture Subject to a Healing Test
    The expression of TIEG 1 is evaluated under the effect of treatment with Ouessant black bee royal jelly (0.01%) on an in vitro healing model of FHN in culture.
    2.1. Cell processing
    HLFs from an abdominoplasty of a 37-year-old Caucasian woman are seeded at the rate of 80,000 cells per dish 35 ibidi treat in DMEM medium low in glucose implemented with 10% FCS and a mixture of 'antibiotics (Penicillin / Streptomycin) and maintained in culture for 48 hours, then the medium is changed and replaced by depiliated medium in SVF.
    After 24 hours of culture without SVF, the FHN are treated with royal jelly of Ouessant's black bee at a dose of 100 pg / ml.
    After 15 hours of treatment, a wound on the FHN mat of each Petri dish is made using a cone, in the shape of a cross.
    24 hours after the injury, the culture medium is removed and the TIEG1 immunostaining is performed.
    The cells are fixed with formalin and then permeabilized with triton (0.1%) for 10 minutes. They are then saturated with 1% PBS / BSA ("Phosphate Buffer Saline", "Bovine Serum Albumin") for 30 minutes. The primary antibody (rabbit anti-KLF10; Abcam) is diluted 1/200 th in 1% PBS-BSA buffer and incubated on the cells at room temperature for 1 hour. After rinsing with PBS, the secondary antibody (“Alexa Fluor® 568 Goat Anti-Rabbit IgG”) is diluted 1/200 th in 1% PBS-BSA buffer and deposited at room temperature for 1 hour in the dark . Labeling of the nuclei with DAPI (diluted 1/100 th ) and actin filaments with phalloidin 488 (diluted 1/200 th ) is carried out in parallel with the incubation of the secondary antibody.
    After rinsing with PBS, a few drops of aqueous mounting medium are added. The boxes are finally stored at 4 ° C while awaiting image acquisition under a fluorescence microscope.
    2.2. Confocal microscope image acquisition and analysis
    The images are taken with a Leica SP5 II confocal microscope with the x20 air objective at a resolution of 1024 x 1024 pixels. Three images are taken in the non-injured area and three or more images in the injured area, with the same acquisition parameters. The images are taken after excitation of the fluorochromes by a specific laser: 1. Argon laser (488 nm), 2. laser diode (405 nm) and 3. helium-neon laser ”(633 nm).
    Once the acquisitions have been made, the images are analyzed one by one using Leica QWin software, in order to obtain a quantitative description.
    An image analysis program allows specific detection of nuclei and TIEG-1 labeling. The detection of the labeling of TIEG-1 is carried out in the cytoplasmic compartment and in the nucleus of the cells. For each condition, the quantification of TIEG-1 is measured in the scar area and in the uninjured area. The values of this quantification are systematically weighted by the number of nuclei or the cell surface.
    2.3. Results
    The results (Figure 2) are grouped in Table 1 below for the uninjured and injured areas (scar area).
    Table 1: Nuclear expression of TIEG1 in the uninjured area and in the scarred area treated with Ouessant black bee royal jelly or untreated.
    Processing conditions TIEG expression Cores / cell Average Standard deviation Uninjured area Untreated witness 12.9 0.6 Ouessant black bee royal jelly (100pg / ml) 102.7 6.5 Scar area Untreated witness 14.9 2.1 Ouessant black bee royal jelly (100pg / ml) 126.8 12.5
    Ouessant's black bee royal jelly induced a significant increase in the nuclear expression of TIEG1 compared to the untreated control by + 700% in the uninjured area and + 751% in the scar area (Figure 2).
    Furthermore, it should be noted that treatment with Ouessant black bee royal jelly increases the expression of TIEG1 in the nuclear compartment of the cells of the scar zone by 23% compared to the expression of TIEG-1 after treatment of cells in the uninjured area, against 16% for the untreated witness.
    Thus, treatment with Ouessant black bee royal jelly acts more effectively on a scar area, which makes it particularly interesting for use as an anti-aging agent in cosmetic skin care compositions intended to prevent or slow down the appearance of signs of intrinsic or extrinsic aging of the skin.
    Example 3 Study of the Effect of Ouessant Black Bee Royal Jelly and Black Striped Yellow Bee Royal Jelly (Buckfast Bee) on the Expression of Collagen V and Elastin in Normal Human Fibroblasts ( FHN) in culture
    3.1. Cell treatments
    The FHN are sown in T75 flasks (75 cm2 flask, BD Biosciences) in DMEM medium (Dulbecco’s modified Eagle’s medium) supplemented with 10% fetal calf serum
    The FHN are trypsinized at confluence with a 0.05% trypsin-EDTA solution, and neutralized with a medium containing serum. Then they are seeded in 2 24-well plates at the rate of 38,000 cells per well.
    The HLFs are then treated (or not) with royal jelly of Ouessant's black bee or black striped yellow bee (Buckfast bee) tested at concentrations of 100 pg / ml for 6 days. The black striped yellow bee comes from the cross of the bee subspecies Apis mellifera mellifera and Apis mellifera ligustica. The treatment is performed in duplicate for each condition and repeated 3 times during these 6 days. For the NT control conditions (untreated), the medium is replaced by new medium.
    After 6 days of treatment, the cells are rinsed twice with phosphate buffer, then fixed with formalin (10% solution) for 10 minutes. After 2 rinses with PBS, the cell membranes are permeabilized with a solution of PBS / Triton X-100 0.1% (Sigma), then rinsed twice with phosphate buffer.
    The cells are covered with a solution of 1% bovine serum albumin in phosphate buffer, for 30 minutes and at room temperature.
    The PBS / BSA is then replaced with primary antibody solution for each labeled protein (see Table 2 below) diluted 1/100 in PBS / 1% BSA.
    Table 2: Summary of the antibodies used
    Primary Antibody Secondary Antibody Collagen V Novotec 20511, Rabbit at 1/500 th Alexa fluor 568 Goat Anti Rabbit (Molecular Probes) at 1/200 th Elastin Novotec 25011, Rabbit at 1/200 th
    The plates are incubated for 2 hours at room temperature.
    The cells are then rinsed with phosphate buffer and covered with a solution of secondary antibody according to the primary antibody to be targeted (Table 2) and of DAPI (4 ', 6'-diamidino-2-phenylindole, dihydrochloride) respectively at 1/200 th and at 1/100 th in a 1% bovine serum albumin solution in 1% phosphate buffer. The plates are kept for one hour in the dark and at room temperature.
    The secondary antibody solution is then aspirated and the cells rinsed with PBS and then with distilled water. A few drops of mounting medium (Aqua-Mount, Lab Vision Thermo Scientific) are deposited in each well.
    3.2. Acquisition and analysis of images by High-Content Screening (HCS)
    The plates are scanned with "ArrayScan XTi" (Thermo Cellomics).
    Acquisition conditions:
    Detection: - DAPI: filter XF53_386_23
    - Alexa Fluor 568: filter XF53_572_15
    - Resolution: 1104 x 1104
    - Objective: 10x sec
    - Number of images: 49 per well (i.e. 2 x 49 = 98 per condition)
    The images are analyzed using image analysis software ("Spot detector"), which detects the red marking of the targeted protein, corresponding to the expression thereof. The area of the measurement area corresponds to the entire area of the image. The number of cells is determined by counting the nuclei by detecting the blue marking.
    3.3. Results
    at. Expression of type V collagen
    Ouessant's black bee royal jelly significantly increases the synthesis of type V collagen on HLF compared to the untreated control (Figure 3).
    Ouessant's black bee royal jelly also has a significantly greater effect than that observed for black striped yellow bee royal jelly (Buckfast bee) (Figure 3).
    b. Elastin expression
    Ouessant's black bee royal jelly very significantly increases (+ 66.8%) the synthesis of elastin on FHN (Figure 4).
    The results obtained on different targets involved in the synthesis of the extracellular matrix in FHN shows that the royal jelly of black bees from Ouessant has an activating effect on the expression of collagen type V and elastin, which is significantly higher than that measured for royal yellow striped black bee jelly (Buckfast bee). No particular effect on the expression of type collagen
    V and elastin are only seen in NHFs treated with royal yellow striped black bee jelly.
    On the contrary, the royal jelly of yellow striped black bee showed that it significantly decreased (-13.2%) the synthesis of type V collagen on HLF compared to the untreated control.
    Example 4: SPF 15 day cream
    The composition below is an oil-in-water emulsion.
    Ouessant's black bee royal jelly is identified by a high content of 10-hydroxy-2-decenoic acid compared to the content of this compound in a yellow striped black bee jelly (Buckfast).
    The percentages are expressed by weight relative to the final composition:
    Ouessant black bee royal jelly 0.01
    Octocrylen2.0
    Octyl methoxycinnate7.5
    Ethyl 2 hexyl palmitate4.0
    Phenyl trimethicone0,5
    Glyceryl monostearate0,2
    Cetearyl alcohol / dicetylphopshate / ceteth-10 phosphate2,0
    Glyceryl stearate / PEG-100 stearate2.0
    Cetyl alcohol 2.0
    Beeswax Polyglyceryl-30,4
    Benzophenone-31.5
    Caprylic / caric triglyceride3.5
    Butylene glycol dicaprylate / dicaprate2,5
    C12-15 alkyl benzoate / titanium dioxide / polyhydroxystearic acid / aluminum stearate / alumina2,5
    Sodium polyacrylate 0.6
    Butylene glycol 2.0
    Diglycerin1.0
    Glycerol3.5
    Sodium hyaluronate <0.1
    0.2 xanthan gum
    Ammonium acryloyldimethyltaurate / VP copolymer 0.4
    Citric acid <0.1
    Trisodium citrate 0.1
    Octenyl aluminum starch succinate 1.5
    Rosemary leaf extract solution 2.0
    Silk tree bark extract solution (PRODIZIA®) 2.0
    Tocopheryl acetate 0.2
    Adjuvants (perfumes, basifying, preservatives) qs
    Purified water qs 100
    Ouesssant black bee royal jelly is a paste which is dissolved in the aqueous continuous phase of the cream.
    Each phase is prepared separately and then the fatty phase is added with stirring to the aqueous phase so as to obtain a homogeneous dispersion of the fatty phase droplets in the continuous phase.
    The cream has a particularly pleasant texture on application. It is applied on waking, on the face, by a light massage, emphasizing the areas showing signs of aging such as wrinkles or fine lines or areas showing sagging skin.
    BIBLIOGRAPHICAL REFERENCES
    Biofactors, 2010, 36, 8-18)
    Gumez L. et al., J. Appl. Physiol., 2010, 108, 1706-1710
    Paul Martin, Wound Healing-Aiming for Perfect Skin Régénération, Science, 1997, 276, 5309, pp. 75-81.
    Snyder L.R. Journal Of Chromatography, vol. 92, 1974, pages 223 - 230
    Subramaniam M. et al. Mol. Cell. Biol., 2005, 1191-1199
    Subramaniam Ai. et al., Biofactors, 2010, 36, 8-18
    Taguchi M. et al., J. Musculoskelet. Res., 2008, 11, 63-69
    权利要求:
    Claims (7)
    [1" id="c-fr-0001]
    1. Cosmetic composition characterized in that it includes royal jelly of Ouessant's black bee in a cosmetically acceptable medium.
    [2" id="c-fr-0002]
    2. Cosmetic composition according to claim 1, characterized in that it comprises said royal jelly at a concentration of 0.001% and 1%, preferably 0.005% and 0.5% and even more preferably between 0.05% and 0.2 % by weight of the total composition.
    [3" id="c-fr-0003]
    3. Cosmetic composition according to claim 1 or 2, for its topical use intended to stimulate the regeneration of the skin and / or scarring.
    [4" id="c-fr-0004]
    4. Cosmetic composition according to any one of claims 1 to 3, characterized in that said composition comprises one or more cosmetically acceptable excipients.
    [5" id="c-fr-0005]
    5. Cosmetic composition according to claim 4, characterized in that said cosmetically acceptable excipient is selected from polymers, surfactants, rheology agents, perfumes, electrolytes, pH adjusters, antioxidants, preservatives, dyes, pearlescent agents, pigments and their mixtures.
    [6" id="c-fr-0006]
    6. Cosmetic composition according to any one of claims 1 to 5, in that it is in the form of oil-in-water or water-in-oil emulsions, cream, oil, milk, lotions, serum, preferably under form of cream or serum.
    [7" id="c-fr-0007]
    7. Cosmetic composition according to any one of claims 1 to 6, in that it further comprises a unifloral or polyfloral honey or a honey extract, preferably a clover honey (Trifolium repens) or spurge.
    A: apart from the injury
    B: injury and outside the injury
    C: p * el injury, / ccl i ‘/ 41; "N <·" >> ’<". .m ,. Λ> 'ΐ <· | .!> M Ltb ’. 'W.ir, - (./.- 1 -..- /. 1.41, Zone A Zone B Zone C
    类似技术:
    公开号 | 公开日 | 专利标题
    EP3558468B1|2021-01-27|Cosmetic composition comprising royal jelly of the ouessant black bee
    FR3057462B1|2019-08-09|ANIGOZANTHOS FLAVIDUS EXTRACT FOR ITS COSMETIC USE
    TW201206495A|2012-02-16|Compositions and methods for stimulating MAGP-1 to improve the appearance of skin
    FR2957252A1|2011-09-16|COSMETIC COMPOSITION
    EP0946138B1|2003-02-26|Use of a potentilla erecta extract in the cosmetic and pharmaceutical field
    CA2908628C|2021-06-08|Synergistic combination of alanine-glutamine, hyaluronic acid and an oat extract and the use thereof in a composition intended for healing wounds and repairing skin lesions
    JP6049119B2|2016-12-21|Ran Vanda Cerulea as a cosmetic active agent
    US20190125657A1|2019-05-02|Cosmetic use of khaya senegalensis extract
    FR3061018A1|2018-06-29|COSMETIC COMPOSITION COMPRISING ALBIZIA JUBIBRISSIN EXTRACT, ROSEMARY EXTRACT AND ROYAL JELLY
    FR3051369B1|2019-06-14|BEET HINT EXTRACTS, COMPOSITIONS AND USES
    WO2015036704A1|2015-03-19|Cosmetic or dermatological use of an extract of tapirira guianensis
    FR3010307A1|2015-03-13|COSMETIC OR DERMATOLOGICAL USE OF AVICULARIN
    WO2020115435A1|2020-06-11|Garcinia mangostana extract for promoting hair growth
    JP2020518593A|2020-06-25|Use of Nepherium lapaceum extract for increasing the hardness of skin and/or mucous membrane
    WO2020249382A1|2020-12-17|Cosmetic use of an extract of golden grass |
    FR3080026A1|2019-10-18|PLANT EXTRACTS CONTAINING POLYGODIAL, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC AND / OR DERMATOLOGICAL USES
    CN111148506A|2020-05-12|Method of using Let-7b inhibitors in cosmetic and/or nutraceutical products
    KR20170035658A|2017-03-31|Composition for improving skin comprising cryptochlorogenic acid as active ingredient
    FR3019988A1|2015-10-23|COSMETIC USE OF INTYBUS CHICORIUM EXTRACT
    FR2986708A1|2013-08-16|COMPOSITION BASED ON APPLE SHEET EXTRACT FOR SKIN SLURRY
    同族专利:
    公开号 | 公开日
    JP2020503319A|2020-01-30|
    KR20190119033A|2019-10-21|
    US11020342B2|2021-06-01|
    US20190374460A1|2019-12-12|
    FR3061017B1|2020-03-20|
    ES2865853T3|2021-10-18|
    EP3558468B1|2021-01-27|
    CN110312551A|2019-10-08|
    WO2018115448A1|2018-06-28|
    EP3558468A1|2019-10-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP1438964A1|2001-09-27|2004-07-21|Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo|Process for producing collagen production enhancers and use thereof|
    US20090068128A1|2007-09-10|2009-03-12|Waddington Tauna A|Scar and rosacea and other skin care treatment composition and method|
    US20110268812A1|2010-03-09|2011-11-03|Lvmh Recherche|Cosmetic or dermatological composition comprising the combination of honey and a peptide|
    JP2008110927A|2006-10-30|2008-05-15|Yamada Bee Farm Corp|Cosmetic containing royal jelly protein hydrolyzate|
    FR2955770B1|2010-02-03|2016-05-13|Lvmh Rech|COSMETIC COMPOSITION.|
    CN103505378A|2012-06-20|2014-01-15|郑锦芬|Anti-light aging preparation for skin|FR3090382B1|2018-12-20|2021-01-29|Lvmh Rech|Spurge honey as an active ingredient that promotes tissue regeneration|
    FR3096263A1|2019-05-24|2020-11-27|L V M H Recherche|Cosmetic use of honey as a protective active ingredient for the skin sensory system|
    FR3096261A1|2019-05-24|2020-11-27|L V M H Recherche|Summer honey from the Åland archipelago as an anti-aging active|
    FR3096262A1|2019-05-24|2020-11-27|L V M H Recherche|Forest honey from Ikaria Island as an anti-aging active|
    KR102267099B1|2019-11-19|2021-06-22|주식회사 고운세상코스메틱|Cosmetic composition with excellent skin elasticity and wrinkle improvement|
    法律状态:
    2017-11-20| PLFP| Fee payment|Year of fee payment: 2 |
    2018-06-29| PLSC| Publication of the preliminary search report|Effective date: 20180629 |
    2019-11-20| PLFP| Fee payment|Year of fee payment: 4 |
    2020-11-20| PLFP| Fee payment|Year of fee payment: 5 |
    2021-11-18| PLFP| Fee payment|Year of fee payment: 6 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1663154|2016-12-22|
    FR1663154A|FR3061017B1|2016-12-22|2016-12-22|COSMETIC COMPOSITION COMPRISING ROYAL BLACK BEE JELLY OF OUESSANT|FR1663154A| FR3061017B1|2016-12-22|2016-12-22|COSMETIC COMPOSITION COMPRISING ROYAL BLACK BEE JELLY OF OUESSANT|
    PCT/EP2017/084402| WO2018115448A1|2016-12-22|2017-12-22|Cosmetic composition comprising royal jelly of the ouessant black bee|
    CN201780086746.0A| CN110312551A|2016-12-22|2017-12-22|The cosmetic composition of royal jelly comprising Wei Sanghei bee|
    KR1020197021293A| KR20190119033A|2016-12-22|2017-12-22|Cosmetic composition comprising royal pair of Wispair Black Bee|
    US16/472,314| US11020342B2|2016-12-22|2017-12-22|Cosmetic composition comprising royal jelly of the Ouessant black bee|
    EP17825239.1A| EP3558468B1|2016-12-22|2017-12-22|Cosmetic composition comprising royal jelly of the ouessant black bee|
    ES17825239T| ES2865853T3|2016-12-22|2017-12-22|Cosmetic composition comprising Ouessant's black bee royal jelly|
    JP2019534686A| JP2020503319A|2016-12-22|2017-12-22|Cosmetic composition containing wessan black bee royal jelly|
    [返回顶部]